The stroke pharmacopeia: Promising experimental therapies

Pharmacotherapy

Volumn 18, Issue 3 II SUPPL., 1998, Pages

  Gengo, Francis M ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b MILLARD FILLMORE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; ALTEPLASE; ANCROD; APTIGANEL; BENZOTHIAZOLE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; DIZOCILPINE; ELIPRODIL; FIBRINOLYTIC AGENT; KETAMINE; LUBELUZOLE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NICARDIPINE; NIMODIPINE; PHENCYCLIDINE; PLACEBO; PROUROKINASE; SCAVENGER; TIRILAZAD;

CLINICAL TRIAL; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; PATHOPHYSIOLOGY; REVIEW; STROKE;

CALCIUM CHANNEL BLOCKERS; CEREBROVASCULAR DISORDERS; FREE RADICAL SCAVENGERS; HUMANS; NEUROPROTECTIVE AGENTS; RECEPTORS, N-METHYL-D-ASPARTATE; THROMBOLYTIC THERAPY;

EID: 0031834051     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Lassen NA. Pathophysiology of brain ischemia as it relates to the therapy of acute ischemic stroke. Clin Neuropharmacol 1990;13(suppl 3):S1-8.
2. Pulsinelli W. Pathophysiology of acute ischaemic stroke. Lancet 1992;339:533-6.
3. Jones TH, Morawetz RB, Crowell RM, et al. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg 1981;54:773-82.
4. Dorman PJ, Sandercock PAG. Considerations in the design of clinical trials of neuroprotective therapy in acute stroke. Stroke 1996;27:1507-15.
5. Fisher M. Potentially effective therapies for acute ischemic stroke. Eur Neurol 1995;35:3-7.
6. Dorman PJ, Counsell CE, Sandercock PAG. Recently developed neuroprotective therapies for acute stroke: a qualitative systematic review of clinical trials. CNS Drugs 1996;5:457-74.
7. Zivin JA, Choi DW. Stroke therapy. Sci Am 1991;265:56-63.
8. Luer MS, Rhoney DH, Hughes M, et al. New pharmacologic strategies for acute neuronal injury. Pharmacotherapy 1996;16:830-48.
9. Alborch E, Salom J, Torregrosa G. Calcium channels in cerebral arteries. Pharmacol Ther 1995;68:1-34.
10. Elben U, Kitter B, Rudolphi K. Stroke therapy research: current trends. Drugs Today 1992;28:333-51.
11. Gelmers HJ, Gorter K, de Weerdt CJ, et al. A controlled trial of nimodipine in acute ischemic stroke. N Engl J Med 1988;318:203-7.
12. Martinez-Vila E, Guillen F, Villanueva JA, et al. Placebo-controlled trial of nimodipine in the treatment of acute ischemic cerebral infarction. Stroke 1990;21:1023-8.
13. TRUST Study Group. Randomized, double-blind, placebo-controlled trial of nimodipine in acute stroke. Lancet 1990;336:1205-9.
14. The American Nimodipine Study Group. Clinical trial of nimodipine in acute ischemic stroke. Stroke 1992;23:3-8.
15. Kaste M, Fogelholm R, Erila T, et al. A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. Stroke 1994;25:1348-53.
16. Limburg M, Horn J, Vermenten M. Very early nimodipine use in stroke (VENUS). Stroke 1996;27:361.
17. Brown CM, Calder C, Linton C, et al. Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischemia. Br J Pharmacol 1995;115:1425-32.
18. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995;26:503-13.
19. Edwards K, and the CNS 1102-008 Study Group. Cerestat (aptiganel hydrochloride) in the treatment of acute ischemic stroke: results of a phase II trial. Neurology 1996;46:A424.
20. Grotta J, Clark W, Coull B, et al. Safety and tolerability of the glutamate antagonist CGS 19755 (selfotel) in patients with acute ischemic stroke: results of a phase IIa randomized trial. Stroke 1995;26:602-5.
21. Anonymous. Ciba suspends selfotel trials. Scrip, December 11, 1995;2086:25.
22. Hargreaves RJ, Hill RG, Iversen LL. Neuroprotective NMDA antagonists: the controversy over the potential for adverse effects on cortical neuronal morphology. Acta Neurochir Suppl (Wien) 1994;60:15-9.
23. Patat A, Molinier P, Hergueta T, et al. Lack of amnestic, psychotomimetic or impairing effect on psychomotor performance of eliprodil, a new NMDA receptor antagonist. Int J Clin Psychopharmacol 1994;9:155-62.
24. Giroux C, Scatton B. Ischemic stroke: treatment on the horizon. Eur Neurol 1996;36:61-4.
25. Modell S, Nober D, Holzbach R. Efficacy and safety of an opiate sigma-receptor antagonist (SL 82.0715) in schizophrenic patients with negative symptoms: an open dose-range study. Psychopharmacology 1996;29:63-6.
26. Anonymous. Searle gears up to move new chemical entities into Phase III. Scrip, October 4, 1996;2169:9.
27. Woodward RM, Huettner JE, Guastella J, et al. In vitro pharmacology of ACEA-1021 and ACEA-1031: systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites. Mol Pharmacol 1995;47:568-81.
28. De Ryck M, Keersmaekers R, Duytschaever H, et al. Lubeluzole protects sensorimotor function and reduces infarct size in a photochemical stroke model in rats. J Pharmacol Exp Ther 1996;279:748-58.
29. De Ryck M, De Prins E, Nolten C, et al. Lubeluzole improves ischemic penumbra measured by cortical spreading depressions in rats. Soc Neurosci Abstr 1995;21:1031.
30. Scheller D, De Ryck M, Lesage A, et al. Lubeluzole reduces extracellular glutamate in the peri-infarct zone of a thrombotic infarct in rats. Soc Neurosci Abstr 1995;21:1027.
31. Lesage AS, Peeters L, Leysen JE. Lubeluzole, a novel long-term neuroprotectant, inhibits the glutamate-activated nitric oxide synthase pathway. J Pharmacol Exp Ther 1996;279: 759-66.
32. Diener HC, Hacke W, Hennerici M, et al. Lubeluzole in acute ischemic stroke. Stroke 1996;27:76-81.
33. Hacke W, Hennerici H, Hantson L, et al. Lubeluzole - a new neuroprotectant agent in the treatment of acute ischemic stroke: results of a cardiovascular safety study in stroke patients. Neurology 1996;46:A429.
34. Grotta J for the U.S. and Canadian Lubeluzole Ischemic Stroke Study Group. Lubeluzole treatment of acute ischemic stroke. Stroke 1997;28:2338-46.
35. Diener HC, for the European and Australian Lubeluzole Ischaemic Stroke Study Group: Multinational randomized trial of lubeluzole in acute ischaemic stroke. Cerebrovasc Dis 1998;8:176-85.
36. The LUB-INT-13 Study Group. Lubeluzole in acute ischemic stroke treatment: an international, placebo-controlled, phase III efficacy trial. Poster presented at the 22nd International Joint Conference on Stroke and Cerebral Circulation, February 6-8, 1997, Anaheim, California.
37. Grotta JC. Pharmacologic modification of acute cerebral ischemia. In: Barnett HJM, Mohr JP, Stein BM, Yatsu FM. Stroke: Pathophysiology, diagnosis, and management, 2nd ed. New York: Churchill Livingstone, 1992;943-51.
38. Clark WM, Hazel JS, Coull BM. Lazaroids: CNS pharmacology and current research. Drugs 1995;50:971-83.
39. Hall ED, Braughler JM, McCall JM. Role of oxygen radicals in stroke: effects of the 21-aminosteroids (lazaroids). A novel class of antioxidants. Prog Clin Biol Res 1990;361: 351-62.
40. Lesiuk H, Sutherland G, Peeling J, et al. Effect of U74006F on forebrain ischemia in rats. Stroke 1991;22:896-901.
41. Orozco J, Mendel RC, Hahn MR, et al. Influence of a 'brain protector' drug 21-amino steroid on the effects of experimental embolic stroke treated by thrombolysis. Neurol Res 1995;17:423-5.
42. The STIPAS Investigators. Safety study of tirilazad mesylate in patients with acute ischemic stroke (STIPAS). Stroke 1994;25:418-23.
43. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
44. Stringer KA. Biochemical and pharmacologic comparison of thrombolytic agents. Pharmacotherapy 1996;16:119S-26.
45. del Zoppo GJ, Higashida RT, Furlan AJ, et al. The prolyse in acute cerebral thromboembolism trial (PROACT): results of 6 mg dose tier. Stroke 1996;27:164.
46. del Zoppo GJ, Higashida RT, Furlan AJ. The case for a phase III trial of cerebral intraarterial fibrinolysis. Am J Neuroradiol 1994;15:1217-22.
47. Sherman DG, Barbour P, Levy D, et al. Ancrod for the treatment of acute ischemic brain infarction. Stroke 1994;25:1755-9.
48. Hossmann V, Heiss W, Besermeyer H, et al. Controlled trial of ancrod in ischemic stroke. Arch Neurol 1983;40:803-8.
49. Pollak VE, Glas-Greenwalt P, Olinger CP, et al. Ancrod causes rapid thrombolysis in patients with acute stroke. Am J Med Sci 1990;299:319-25.
50. Anonymous. BASF Pharma's four research and development "gems." Scrip, February 23, 1996;2105:11.